Wegovy May Be Linked to Rare Eye Stroke Risk

Health Points

• A recent study found a potential connection between high-dose semaglutide and a rare condition called ischemic optic neuropathy.
• Researchers analyzing FDA data found Wegovy showed a stronger association with this vision risk than Ozempic.
• Experts recommend working with a licensed physician, adjusting doses slowly, and keeping up with annual eye exams.

A recent study published in the British Journal of Ophthalmology has found a potential connection between high-dose semaglutide and a rare condition known as an “eye stroke.” This condition, medically called ischemic optic neuropathy, can lead to sudden vision loss or total blindness.

Researchers analyzing FDA data discovered that Wegovy, the higher-dose version of the drug, showed a stronger association with this risk than Ozempic. Men appeared to be particularly vulnerable to these vision changes while using the medication for weight loss.

High doses of semaglutide may reduce blood flow to the optic nerve by triggering shifts in blood pressure or hydration levels.

The oral version of the drug, Rybelsus, and the injectable tirzepatide did not show a significant association with vision problems.

Gradual weight loss and maintaining proper hydration may help decrease the risk of blood pressure drops that affect the eyes.

“Untreated obesity, diabetes, and vascular disease damage vision far more commonly than semaglutide does,” says bariatric surgeon Dr. Hector Perez.

“Patients, especially diabetics, should get yearly eye exams to get a baseline prior to starting such medications,” adds obesity medicine expert Dr. Diala Alatassi.

Experts recommend working closely with a licensed physician to slowly adjust doses and monitor overall health. Staying current with annual eye screenings is vital for anyone taking GLP-1 medications to detect early changes in optic health.